Strain Information | |
---|---|
Image | |
BRC No. | RBRC02285 |
Type | Targeted Mutation and Transgene |
Species | Mus musculus |
Strain name | C57BL/6-St3gal4<tm1.1Bsi> |
Former Common name | ST34(#9 CAGCre)C57BL/6J:913 line, 913, C57BL/6-St3gal4<tm1.1Bsi> Tg(CAG-cre)913Bsi |
H-2 Haplotype | |
ES Cell line | |
Background strain | C57BL/6JJcl |
Appearance | black [a/a B/B C/C] |
Strain development | Developed by Dr. Yoshio Hirabayashi, RIKEN BSI in 2004. St3gal4 null allele (St3gal4<tm1.1Bsi>) was generated by transient cre expression MS12 ES cells from St3gal4<tm1Bsi> that having a loxP flanked site in this allele. |
Strain description | St3gal4 (ST3GAL IV) knockout mouse. St3gal4 is one of alpha 2,3-sialyltransferases that is abundantly expressed in adult placenta, ovary, and testis. |
Colony maintenance | Backcross to C57BL/6 (Heterozygote x C57BL/6JJcl)) |
References |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |
---|---|
Gene info | Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter St3gal4ST3 beta-galactoside alpha-2,3-sialyltransferase 49St3gal4<tm1.1Bsi>targeted mutation 1.1, RIKEN BSISiat4c, ST3Gal IV Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter loxPphage P1 loxP9loxP |
Ordering Information | |
---|---|
Donor DNA | mouse ST3Gal IV genomic DNA, phage P1 loxP, CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA) |
Research application | Metabolism Research Mouse Models for Human Disease |
Specific Term and Conditions | The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 1. The RECIPIENT agrees to use BIOLOGICAL RESOURCE only for academic research which is expected to be publicized in scientific papers. 2. The RECIPIENT will obtain a prior written consent on the use of BIOLOGICAL RESOURCE from the DEPOSIOR/DEVELOPER. At the same time, the RECIPENT will give the DEPOSITOR/DEVELOPER the details of the research project using BIOLOGICAL RESOURCE for the DEPOSITOR/DEVELOPER to determine whether research collaboration is appropriate. 3. If the DEPOSITOR/DEVELOPER determines that the informed research project requires collaboration, a separate agreement will be formulated by both parties to establish rules such as handling of the research results. 4. If the DEPOSITOR/DEVELOPER determines that the informed research project does not requie collaboration, the RECIPIENT agrees to cite the literatire(s) designated by the DEPOSITOR/DEVEVLOPER when publicizing the research results obtained from use of BIOLOGICAL RESOURCE, and to discuss with the DEPOSITOR/DEVELOPER when application for any patents is considered. 5. If the RECIPIENT wants to crossbreed BIOLOGICAL RESOURCE with other genetically engineered mice, the RECIPIENT will obtain a prior written consent from the DEPOSITOR/DEVELOPER. 6. The RECIPIENT will not distribute the BIOLOGICAL RESOURCE to any other individual or entity. |
Depositor | Yoshio Hirabayashi (RIKEN) |
Strain Status | Frozen embryos |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved embryos (within 1 month) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
---|
Srimontri P, Endo S, Sakamoto T, Nakayama Y, Kurosaka A, Itohara S, Hirabayashi Y, Kato K. Sialyltransferase ST3Gal IV deletion protects against temporal lobe epilepsy. J Neurochem 131(5) 675-87(2014) 25066807 Fujita A, Okuno T, Oda M, Kato K. Urinary volatilome analysis in a mouse model of anxiety and depression. PLoS One 15(2) e0229269(2020) 32084196 Kato K. Differential effects of dietary oils on emotional and cognitive behaviors. PLoS One 10(3) e0120753(2015) 25799588 |